GlaxoSmithKline’s ViiV Healthcare launches new study of HIV regimen

GlaxoSmithKline's global specialist HIV business ViiV Healthcare has announced the launch of a phase III trial programme to assess a promising new HIV regimen.

ViiV Healthcare, which is majority-owned by GlaxoSmithKline and counts Pfizer and Shionogi as shareholders, is commencing two phase III studies to evaluate an investigational long-acting, injectable regimen of cabotegravir and rilpivirine for the treatment of HIV-1.

The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug injectable regimen in both treatment-naive and treatment-experienced patients.

This new regimen is being co-developed as part of a collaboration with Janssen, the creator of rilpivirine. It is hoped that the availability of long-acting injectable therapies could help to improve adherence and patient outcomes compared to drugs that need to be taken more often.

Dr John Pottage, chief scientific and medical officer of ViiV Healthcare, said: "Currently, the treatment of HIV involves lifelong therapy with multiple antiretrovirals, so it is important that we continue to improve on the durability, safety, tolerability and convenience of treatment regimens."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.